We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
-26.05%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$58.9M
AUM Growth
-$94.4M
Cap. Flow
-$59M
Cap. Flow %
-100.17%
Top 10 Hldgs %
100%
Holding
15
New
–
Increased
–
Reduced
5
Closed
7

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
GMED icon
Globus Medical
GMED
+$18.5M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$17.9M
3
UTHR icon
United Therapeutics
UTHR
+$6.72M
4
RACB
Research Alliance Corp. II Class A Common Stock
RACB
+$2.93M
5
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
+$2.93M

Sector Composition

Rank Sector Weight
1 Healthcare 99.51%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNDM icon
1
Tandem Diabetes Care
TNDM
$1.3B
$17.1M 29.07%
147,327
-153,337
-51% -$17.9M
SLN
2
Silence Therapeutics
SLN
$549M
$12.4M 21.08%
654,108
-104,145
-14% -$2.08M
SRZN icon
3
Surrozen
SRZN
$242M
$10.5M 17.86%
233,167
– –
GMED icon
4
Globus Medical
GMED
$10.9B
$7.9M 13.4%
107,024
-266,230
-71% -$18.5M
CMPX icon
5
Compass Therapeutics
CMPX
$349M
$4.74M 8.05%
3,500,000
– –
UTHR icon
6
United Therapeutics
UTHR
$26.2B
$4.41M 7.48%
24,563
-35,275
-59% -$6.72M
MLTX icon
7
MoonLake Immunotherapeutics
MLTX
$1.62B
$1.52M 2.58%
137,000
-13,000
-9% -$129K
SRZNW icon
8
Surrozen Inc Warrant
SRZNW
$69.7K
$291K 0.49%
1,165,832
– –
ARYE
9
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
– –
-300,000
Closed -$2.91M
PANA
10
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
– –
-200,000
Closed -$1.94M
MSACW
11
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
– –
-33,331
Closed -$24K
MSAC
12
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
– –
-300,000
Closed -$2.92M
RACB
13
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
– –
-300,000
Closed -$2.93M
JYAC
14
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
– –
-300,000
Closed -$2.93M
CMAXW
15
DELISTED
CareMax, Inc. Warrant
CMAXW
– –
-45,960
Closed -$64K

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Consonance Capital Management held 15 positions worth $58.9M, down 62% from $153M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Consonance Capital Management withdrew a net $59M in Q1 2022, closing 7 positions and reducing 5 holdings. Its most notable exit was Research Alliance Corp. II Class A Common Stock, an estimated $2.93M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 90% a quarter earlier, followed by Financials.

  • Consonance Capital Management's biggest Q1 2022 reduction was Globus Medical, cutting an estimated $18.5M.
  • Consonance Capital Management fully exited Research Alliance Corp. II Class A Common Stock in Q1 2022, selling an estimated $2.93M.
  • Consonance Capital Management's ten largest holdings make up 100% of its $58.9M portfolio in Q1 2022.
  • Consonance Capital Management opened 0 new positions and closed 7 in Q1 2022.
  • Consonance Capital Management's portfolio value fell 62% quarter-over-quarter to $58.9M.

Based on Consonance Capital Management's 13F filing for Q1 2022, filed 16 May 2022.